Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

568
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
568
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

490
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
490
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

538
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
538
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

442
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
442
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

605
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
605
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

356
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
356

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct Oral Anticoagulant Type and Dose in Atrial Fibrillation With Decompensated Cirrhosis: A Propensity-Matched Analysis.

Gastro hep advances·2026
Same author

Rhythm-Stratified Performance of an Artificial Intelligence-Electrocardiographic Aortic Stenosis Score: Alignment with Computed Tomography Calcium in Atrial Fibrillation.

Mayo Clinic proceedings. Digital health·2026
Same author

Pulmonary vein anatomical variants and incidence of atrial fibrillation.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026
Same author

Lipoprotein(a) and Risk of Treated Ventricular Arrhythmias in Heart Failure.

JAMA network open·2026
Same author

Z-coded social determinants of health and cardiovascular risk among patients receiving dialysis.

Journal of nephrology·2026
Same author

Artificial intelligence-powered electrocardiogram is superior to NT-proBNP in predicting left ventricular systolic dysfunction in atrial fibrillation with rapid ventricular response.

Heart rhythm O2·2026

Related Experiment Video

Updated: Feb 3, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy.

Pradyumna Agasthi1, Hemalatha Narayanasamy1, Dan Sorajja1

  • 1Department of Cardiovascular Diseases, Mayo Clinic, Arizona 85259, USA.

Case Reports in Cardiology
|October 27, 2018
PubMed
Summary
This summary is machine-generated.

Decitabine, a leukemia treatment, may cause cardiomyopathy. A patient developed heart failure and reduced ejection fraction while on decitabine therapy for secondary acute myelogenous leukemia.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.4K
Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K

Related Experiment Videos

Last Updated: Feb 3, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.4K
Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K

Area of Science:

  • Oncology
  • Pharmacology
  • Cardiology

Background:

  • Decitabine is a hypomethylating agent used to treat myelodysplastic syndromes and leukemia.
  • Its mechanism involves DNA incorporation and inhibition of DNA methyltransferase.
  • Secondary acute myelogenous leukemia (sAML) indicates leukemia developing after prior chemotherapy or radiation.

Observation:

  • A patient with sAML was treated with decitabine.
  • The patient subsequently developed symptoms of new-onset heart failure.
  • Cardiac evaluation revealed a significant decline in ejection fraction.

Findings:

  • The case suggests a potential association between decitabine treatment and the development of cardiomyopathy.
  • This adverse cardiac event occurred in the context of sAML treatment.
  • The observed ejection fraction decline indicates impaired cardiac function.

Implications:

  • Clinicians should monitor patients receiving decitabine for cardiac adverse events.
  • Cardiomyopathy may be an underrecognized side effect of decitabine therapy.
  • Further research is warranted to elucidate the mechanism and incidence of decitabine-induced cardiotoxicity.